Featuring prominently in NeuroNews’ latest top 10 are a number of stories relating to the real-world implementation of mechanical thrombectomy treatments—including a new study emphasising the impact of procedural duration relative to prehospital delays, an industry update demonstrating the ability of robotic systems to enable remote interventions, and multiple US regulatory clearances of the latest artificial intelligence (AI)-powered solutions that look set to advance the stroke care field. A novel research endeavour indicating the feasibility of in-utero embolisation in the treatment of foetal vein of Galen malformation (VOGM) is among highlights from October 2025 too.
1. Procedural duration “exerts a greater influence” on post-thrombectomy functional outcomes compared to prehospital delays
A retrospective analysis of more than 6,600 acute ischaemic stroke patients has revealed that the duration of a mechanical thrombectomy procedure may have a significantly more profound effect on functional outcomes as compared to prehospital delays. The findings of this analysis have been published by Ali Alawieh (Emory University School of Medicine, Atlanta, USA) and colleagues in the Journal of NeuroInterventional Surgery.
2. Remedy Robotics announces first fully remote neurointerventional procedures with N1 system
Remedy Robotics has debuted what it claims is the “world’s first” remotely operable endovascular robotic platform: the Remedy N1 system. A press release from the company notes that, by combining proprietary hardware with AI-enabled software, the N1 system enables clinicians to deliver faster, safer and more effective interventional treatments to patients with conditions including stroke, heart attack, or vascular trauma—whether they are in the same room or on the other side of the globe.
3. Toro Neurovascular and Kaneka announce exclusive US distribution partnership
Toro Neurovascular has announced an exclusive distribution partnership with Kaneka Medical America for Toro’s novel neurovascular catheter portfolio in the US market, pending regulatory clearance.
4. Crossroads announces positive early clinical performance during Path BGC’s limited market release
Crossroads Neurovascular has announced successful early clinical experiences with its newly US Food and Drug Administration (FDA)-cleared Path balloon guide catheter (BGC) during the device’s ongoing limited market release (LMR) phase.
5. Methinks expands stroke detection solution into contrast imaging with second US FDA clearance
Methinks recently announced that it has received US FDA 510(k) clearance for Methinks computed tomography angiography (CTA) Stroke, an AI-based software solution intended to accurately detect suspected large vessel occlusions (LVOs) using CTA scans. This marks the company’s second FDA 510(k) clearance of 2025 after its non-contrast computed tomography (NCCT) Stroke software gained approval from the US regulator in July.
6. Early results indicate feasibility of in-utero embolisation to treat foetal vein of Galen malformation
Preliminary study results published in the Journal of the American Medical Association have shown that in-utero embolisation may be a feasible option in the management of foetal VOGM, having led to improvements in survival and overall outcomes across seven eligible patients treated at a single centre.
7. Boston Scientific announces agreement to acquire Nalu Medical
Boston Scientific Corporation has announced that it has entered into a definitive agreement to acquire Nalu Medical—a company developing minimally invasive solutions for patients with chronic pain. With Boston Scientific having been a strategic investor in Nalu since 2017, the transaction consists of an upfront cash payment of approximately US$533 million for the remaining equity not already owned by Boston Scientific.
8. Penumbra launches SwiftSET neuroembolisation coil
Penumbra has announced that it recently launched its SwiftSET coil—a new, complex coil solution designed for adaptive embolisation. According to the company, SwiftSET is engineered to optimise vessel wall apposition through its shape configuration, and facilitate smooth deployment and natural conformity to tight spaces for dense occlusion in small vessels.
9. Medtronic fully launches Neuroguard IEP system
Medtronic has announced the full distribution of the Neuroguard integrated embolic protection (IEP) system for carotid artery disease following its limited market distribution. This follows the announcement earlier this year of an exclusive US distribution agreement between Medtronic and Contego Medical, the developer of the device.
10. MindRhythm’s prehospital LVO stroke identification device submitted for US FDA clearance
MindRhythm has announced that it has officially submitted a de novo application to the US FDA seeking clearance for its Harmony device designed for prehospital LVO stroke identification.
